CCEL vs VCEL vs BLFS vs IART vs OSUR

For growth investors, BioLife Solutions, Inc.

(BLFS) is the stronger pick with 17. 0% revenue growth year-over-year, versus -38. 1% for OraSure Technologies, Inc. (OSUR). Cryo-Cell International, Inc. (CCEL) offers the better valuation at 69. 0x trailing P/E, making it the more compelling value choice. Analysts rate Vericel Corporation (VCEL) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Cryo-Cell International, Inc.

(CCEL) is the cheapest at 69. 0x versus Vericel Corporation at 109. 8x. On forward P/E, Integra LifeSciences Holdings Corporation is actually cheaper at 5. 8x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, BioLife Solutions, Inc.

(BLFS) delivered a total return of -27. 0%, compared to -81. 7% for Integra LifeSciences Holdings Corporation (IART). Over 10 years, the gap is even starker: BLFS returned +1221% versus IART's -63. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Cryo-Cell International, Inc.

(CCEL) is the lower-risk stock at 0. 35β versus Integra LifeSciences Holdings Corporation's 2. 34β — meaning IART is approximately 565% more volatile than CCEL relative to the S&P 500. On balance sheet safety, OraSure Technologies, Inc. (OSUR) carries a lower debt/equity ratio of 4% versus 195% for Integra LifeSciences Holdings Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), BioLife Solutions, Inc.

(BLFS) is pulling ahead at 17. 0% versus -38. 1% for OraSure Technologies, Inc. (OSUR). On earnings-per-share growth, the picture is similar: Cryo-Cell International, Inc. grew EPS 104. 4% year-over-year, compared to -73. 6% for Integra LifeSciences Holdings Corporation. Over a 3-year CAGR, VCEL leads at 18. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Vericel Corporation (VCEL) is the more profitable company, earning 6.

0% net margin versus -59. 8% for OraSure Technologies, Inc. — meaning it keeps 6. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CCEL leads at 10. 9% versus -59. 2% for OSUR. At the gross margin level — before operating expenses — CCEL leads at 75. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Integra LifeSciences Holdings Corporation (IART) trades at 5.

8x forward P/E versus 156. 4x for BioLife Solutions, Inc. — 150. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BLFS: 42. 7% to $33. 00.

In this comparison, CCEL (7.

1% yield) pays a dividend. VCEL, BLFS, IART, OSUR do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Cryo-Cell International, Inc.

(CCEL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 35), 7. 1% yield). Integra LifeSciences Holdings Corporation (IART) carries a higher beta of 2. 34 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CCEL: +61. 3%, IART: -63. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CCEL is a small-cap income-oriented stock; VCEL is a small-cap high-growth stock; BLFS is a small-cap high-growth stock; IART is a small-cap quality compounder stock; OSUR is a small-cap quality compounder stock. CCEL pays a dividend while VCEL, BLFS, IART, OSUR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.